Repositioning Candidate Details
| Candidate ID: | R0881 |
| Source ID: | DB05829 |
| Source Type: | approved; investigational |
| Compound Type: | biotech |
| Compound Name: | Parathyroid hormone |
| Synonyms: | Parathormone; Parathormone (human recombinant); Parathyrin; Parathyroid hormone; Parathyroid hormone (1-84) human recombinant; Parathyroid hormone (rDNA); PTH; PTH(1-84); rhPTH; rhPTH(1-84); rPTH; rPTH(1-84) |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa). Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA). |
| CAS Number: | 9002-64-6 |
| Molecular Weight: | |
| DrugBank Indication: | For use/treatment in osteoporosis. |
| DrugBank Pharmacology: | Parathyroid hormone is responsible for the fine regulation of serum calcium concentration on a minute-to-minute basis. This is achieved by the acute effects of the hormone on calcium resorption in bone and calcium reabsorption in the kidney. The phosphate mobilized from bone is excreted into the urine by means of the hormone's influence on renal phosphate handling. Parathyroid hormone also stimulates calcium absorption in the intestine, this being mediated indirectly by 1,25-dihydroxyvitamin D. Thus, a hypocalcemic stimulus of parathyroid hormone secretion results in an increased influx of calcium from three sources (bone, kidney, and intestine), resulting in a normalization of the serum calcium concentration without change in the serum phosphate concentration. |
| DrugBank MoA: | The biological actions of rhPTH are mediated through binding to at least two distinct high- affinity cell-surface receptors specific for the N-terminal and C-terminal regions of the molecule, both of which are required for normal bone metabolism. The N-terminal portion of the molecule is primarily responsible for the bone building effects of parathyroid hormone. The C-terminal portion of the molecule has antiresorptive activity and is necessary for normal regulation of N-terminal fragment activity. |
| Targets: | Parathyroid hormone/parathyroid hormone-related peptide receptor activator; Parathyroid hormone 2 receptor activator |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |